Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | CETP | P11597 | 3/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168031 | 1.00 | DEGS1 (0.66) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL22341756 | 0.95 | CNR1 (0.72) | DEGS1CNR1THRBMEN1KMT2A | |
| SCHEMBL7621349 | 0.94 | DEGS1 (0.63) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL7620599 | 0.94 | DEGS1 (0.63) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL7622257 | 0.94 | DEGS1 (0.63) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL7619349 | 0.94 | DEGS1 (0.63) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL14010922 | 0.94 | DEGS1 (0.63) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL23016760 | 0.92 | PLA2G4A (0.65) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL22911005 | 0.92 | PLA2G4A (0.65) | DEGS1CNR1CETPTHRBMEN1 | |
| SCHEMBL22910819 | 0.92 | PLA2G4A (0.65) | DEGS1CNR1CETPTHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985586-B2 | Oligodendrocyte precursor cell composition and methods of use | Georgia Health Sciences University (US) | 2011-07-26 | — | — | US | claimed |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-08-06 | — | — | US | claimed |
| US-7445931-B2 | Culturing differentiating pluripotent human cell with N-palmitoyl serinol or N-oleoyl serinol in serum-free medium; modulating apoptosis | BRESAGEN, INC. (US) | 2008-11-04 | — | — | US | claimed |
| US-7985586-B2 | Oligodendrocyte precursor cell composition and methods of use | Georgia Health Sciences University (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090035285-A1 | Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs | BRESAGEN, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-7445931-B2 | Culturing differentiating pluripotent human cell with N-palmitoyl serinol or N-oleoyl serinol in serum-free medium; modulating apoptosis | BRESAGEN, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20060183221-A1 | Method for neural differentiation of embryonic stem cells using protease passaging techniques | BRESAGEN, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060014280-A1 | Culturing differentiating pluripotent human cell with N-palmitoyl serinol or N-oleoyl serinol in serum-free medium; modulating apoptosis | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-01-19 | — | — | US | disclosed |
| WO-2004029203-A2 | COMPOSITIONS AND METHODS FOR ENRICHMENT OF NEURAL STEM CELLS USING CERAMIDE ANALOGS | BRESAGEN, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035285-A1 | Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs | SMPD4, NOTCH4, SGMS1 | DEGS1 57/4885CNR1 496/4885CETP 99/4885 |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | SGMS1, S1PR1, S1PR3 | DEGS1 22/4885CNR1 35/4885CETP 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.